Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Big pharma and biotech partnerships are necessary to maintain innovation in drugs and medicine

NoëL Brown, 10-5-2021, "RBC Capital Markets", https://www.rbccm.com/en/gib/biopharma/episode/biotech-and-big-pharma-blueprint-for-successful-partnership, 7-3-2022, //ms

Strategic partnerships have long been an important contributor to how drugs are discovered. For decades, big pharma companies have been forming alliances with smaller biotech innovators to increase R&D productivity. From the biotech’s perspective pharma expands the geographical reach of a drug and aids in better managing late-stage development and commercialization costs. Greg Wiederrecht, Ph.D., Managing Director in the Global Healthcare Investment Banking Group at RBC Capital Markets, is no stranger to the importance of these deals. Before moving to the banking world in 2015, Wiederrecht was the Vice President and Head of External Scientific Affairs (ESA) at Merck, where his group of 85 physicians and scientists was responsible for the identification and scientific assessment of all licensing, collaboration, partnership, and acquisition opportunities for Merck worldwide. Wiederrecht’s experience gives him a unique perspective on why partnerships are vital for both biotech and big pharma companies. A question of scale “It’s impossible for large pharma companies to work in every single sub-therapeutic area out there,” explains Wiederrecht. “In today's markets, the vast majority of approved drugs are associated with some type of licensing partnership or acquisition component. Even the largest companies can only work on so many targets at once, whereas there are hundreds of thousands of researchers in academia and biotechs out there who can specialize in vastly more diseases and afflictions. If one of them makes a discovery that satisfies an unmet medical need, then large pharma can form some type of strategic partnership or collaboration to provide a jump start on their competitors.” The path to innovation So, what exactly does a strategic partnership entail? According to Wiederrecht, partnerships can take many forms. “It can be something as minor as a feasibility study on a potential partner's asset, or something more significant like a research collaboration, patent license, development commercialization agreement, or even an acquisition. In fact, many acquisitions begin with a collaboration that went so well the pharma wants to acquire the entire biotech. We've certainly seen some examples of that recently.” Evaluating potential Clearly, big pharma is dependent on collaborative alliances. But from a biotech perspective, when is a strategic partnership the best path forward? “Strategic partnerships can be essential to a biotech for several reasons. A biotech may have a patent position on a novel target. However, it may not have the volume of chemists and preclinical development experts that a big pharma can muster to get through what we call the ‘zone of chaos’ in drug development, which largely involves solving toxicity issues that can lead to unwanted surprises in clinical development.” “Also, if a biotech is working on a project in a large-scale indication that afflicts hundreds of thousands of people, the clinical trial costs may be too much for them to endure”, continues Wiederrecht. “Commercialization – particularly for those larger indications – is something big pharma excels in. They have established infrastructures in most countries around the world to sell the product.”

Sign in to recut, update, or save this card.